Минимальная остаточная болезнь при В-клеточном хроническом лимфолейкозе

1. Vuillier F, Claisse JF, Vandenvelde C et al. Evaluation of residual disease in B-cell chronic lymphocytic leukemia patients in clinical and bone-marrow remission using CD5-CD19 markers and PCR study of gene rearrangements. Leuk. Lymphoma 1992; 7 (3): 195–204.
2. Bottcher S, Ritgen M, Pott C et al. Comparative analysis of minimal residual disease detection using four-color flow cytometry, consensus IgH-PCR, and quantitative IgH PCR in CLL after allogeneic and autologous stem cell transplantation. Leukemia 2004 Oct; 18 (10): 1637–45.
3. Provan D, Bartlett-Pandite L, Zwicky C et al. Eradication of polymerase chain reaction-detectable chronic lymphocytic leukemia cells is associated with improved outcome after bone marrow transplantation. Blood 1996 Sep 15; 88 (6): 2228–35.
4. Bruggemann M, Droese J, Bolz I et al. Improved assessment of minimal residual disease in B cell malignancies using fluorogenic consensus probes for real-time quantitative PCR. Leukemia 2000 Aug; 14 (8): 1419–25.
5. Kneba M. Evaluating of MRD in CLL. Vth international workshop of the german CLL study group. 2004.
6. Vuillier F, Claisse JF, Vandenvelde C et al. Evaluation of residual disease in B-cell chronic lymphocytic leukemia patients in clinical and bone-marrow remission using CD5-CD19 markers and PCR study of gene rearrangements. Leuk. Lymphoma 1992; 7 (3): 195–204.
7. Clavio M, Miglino M, Spriano M et al. First line fludarabine treatment of symptomatic chronic lymphoproliferative diseases: clinical results and molecular analysis of minimal residual disease. Eur J Haematol 1998; 61 (3): 197–203.
8. Vuillier F, Scott-Algara D, Dighiero G. Extensive analysis of lymphocyte subsets in normal subjects by three-color immunofluorescence. Nouv Rev Fr Hematol 1991; 33 (1): 31–8.
9. Fischer M, Klein U, Kuppers R. Molecular single-cell analysis reveals that CD5-positive peripheral blood B cells in healthy humans are characterized by rearranged Vkappa genes lacking somatic mutation. J Clin Invest. 1997 Oct 1; 100 (7): 1667–76.
10. Robertson LE, Huh YO, Butler JJ et al. Response assessment in chronic lymphocytic leukemia after fludarabine plus prednisone: clinical, pathologic, immunophenotypic, and molecular analysis. Blood 1992; 80 (1): 29–36.
11. Lundin J, Kimby E, Bjorkholm M et al. Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath- 1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL). Blood 2002; 100 (3): 768–73.
12. Rawstron AC, Kennedy B, Evans PA et al. Quantitation of minimal disease levels in chronic lymphocytic leukemia using a sensitive flow cytometric assay  improves the prediction of outcome and can be used to optimize therapy. Blood 2001; 98 (1): 29–35.
13. Bosch F, Ferrer A, Lopez-Guillermo A et al: Fludarabine, cyclophosphamide and mitoxantrone in the treatment of resistant or relapsed chronic lymphocytic leukaemia. Br J Haematol 2002; 119: 976–84.
14. Robak T, Blonski JZ, Kasznicki M et al. Cladribine combined with cyclophosphamide is highly effective in the treatment of chronic lymphocytic leukemia. Hematol J 2002; 3 (5): 244–50.
15. Cazin B, Maloum K, Creteil MD et al. Oral fludarabine and cyclophosphamide in previously untreated CLL: final response and follow up in 75 patients. Blood 2003; 102: 438a.
16. Gilleece MH, Dexter TM. Effect of Campath-1H antibody on human hematopoietic progenitors in vitro. Blood 1993 Aug 1; 82 (3): 807–12.
17. Rawstron AC, Kennedy B, Moreton P et al. Early prediction of outcome and response to alemtuzumab therapy in chronic lymphocytic leukemia. Blood 2004 Mar 15; 103 (6): 2027–31.
18. Moreton P, Kennedy B, Lucas G et al. Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival. J Clin Oncol 2005; 23: 2971–9.
19. Montillo M, Cafro AM, Tedeschi A et al. Safety and efficacy of subcutaneous Campath-1H for treating residual disease in patients with chronic lymphocytic leukemia responding to fludarabine. Haematologica 2002; 87: 695–700.
20. Montillo M, Tedeschi A, Rossi V et al. Sequential treatment with fludarabine and subcutaneous alemtuzumab is able to purge residual disease in patients with chronic lymphocytic leukemia. Haematol J 2004; 5 (Suppl. 2): S204.
21. O’Brien SM, Kantarjian HM, Thomas DA et al. Alemtuzumab as treatment for residual disease after chemotherapy in patients with chronic lymphocytic leukemia. Cancer 2003; 98: 2657–63.
22. Wendtner CM, Ritgen M, Schweighofer CD et al. Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission-experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG). Leukemia 2004; 18: 1093–101.
23. Morra E, Nosari A, Montillo M. Infectious complications in chronic lymphocytic leukaemia. Hematol Cell Ther 1999 Aug; 41 (4): 145–51.
24. Kennedy B, Rawstron A, Carter C et al. Campath-1H and fludarabine in combination are highly active in refractory chronic lymphocytic leukemia. Blood 2002; 99: 2245–7.
25. Osterborg A, Dyer MJ, Bunjes D et al: Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia: European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia. J Clin Oncol 1997; 15: 1567–74.
26. Rai KR, Freter CE, Mercier RJ et al. Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine. J Clin Oncol 2002; 20: 3891–7.
27. Elter T, Borchmann P, Schulz H et al. Fludarabine in combination with alemtuzumab is effective and feasible in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: results of a phase II trial. J Clin Oncol 2005: E pub ahead of print, Sep 6.

Е.А.Никитин, Е.М.Грецов

Гематологический научный центр РАМН, Москва